Genetic variations influence everolimus benefit in advanced breast cancer – Healio
|
Genetic variations influence everolimus benefit in advanced breast cancer
Healio Women with hormone receptor-positive, HER-2–negative advanced breast cancer who had minimal genetic variations in PI3K, FGFR or CCND1 derived the most benefit from everolimus therapy, according to study results presented at the Breast Cancer … |
